ETF DAILY NEWS

D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)

D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock. A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their […]

Mar 18, 2025 - 06:57
 0
D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)
D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock. A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their […]
Read More

Tags:

Previous Article

Veritone (NASDAQ:VERI) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

Next Article

Chardan Capital Reaffirms Buy Rating for Avidity Biosciences (NASDAQ:RNA)

Related Posts

Bumble (NASDAQ:BMBL) Price Target Lowered to $6.80 at Citigroup

Bumble (NASDAQ:BMBL) Price Target Lowered to $6.80 at C...

Feb 21, 2025  0

Stifel Nicolaus Cuts Onto Innovation (NYSE:ONTO) Price Target to $250.00

Stifel Nicolaus Cuts Onto Innovation (NYSE:ONTO) Price ...

Feb 10, 2025  0

What is Leerink Partnrs’ Forecast for BEAM Q1 Earnings?

What is Leerink Partnrs’ Forecast for BEAM Q1 Earnings?

Mar 1, 2025  0